Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.28500
Abstract: Key Points Question Is very-low-dose edoxaban (15 mg/day) beneficial across frailty status among very elderly Japanese patients with atrial fibrillation considered ineligible for standard dose oral anticoagulants because of their high bleeding risk? Findings In… read more here.
Keywords: patients atrial; trial; dose edoxaban; atrial fibrillation ... See more keywords
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
Sign Up to like & getrecommendations! Published in 2021 at "Circulation"
DOI: 10.1161/circulationaha.120.052216
Abstract: Supplemental Digital Content is available in the text. Background: Female sex is an independent risk factor for stroke and systemic embolic events in patients with atrial fibrillation. This study aimed to examine the efficacy and… read more here.
Keywords: women men; edoxaban regimen; atrial fibrillation; factor ... See more keywords
Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2022.37.e335
Abstract: Background Non-vitamin K antagonist oral anticoagulants (NOACs) are effective in preventing thromboembolisms and reduce the risk of bleeding compared with warfarin. There are few reports on the outcomes of on-label reduced-dose NOACs. The aim of… read more here.
Keywords: label reduced; patients atrial; edoxaban patients; dose edoxaban ... See more keywords